Literature DB >> 29927123

Synthesis, Characterization, and Function of an RNA-Based Transfection Reagent.

Harsh V Jain1, Jessica F Boehler2,3, Kanneboyina Nagaraju2,4, Serge L Beaucage1.   

Abstract

A synthetic 8-mer, amphipathic, trans-acting poly-2'-O-methyluridylic thiophosphate triester RNA element (2'-OMeUtaPS) can be prepared using solid-phase synthesis protocols. 2'-OMeUtaPS efficiently mediates the delivery of uncharged polyA-tailed phosphorodiamidate morpholino (PMO) sequences in HeLa pLuc 705 cells, as evidenced by flow cytometry measurements. In this cell line, 2'-OMeUtaPS-mediated transfection of an antisense polyA-tailed PMO sequence induces alternative splicing of an aberrant luciferase pre-mRNA splice site, leading to restoration of functional luciferase, as quantitatively measured using a typical luciferase assay. 2'-OMeUtaPS is also potent at delivering an uncharged antisense polyA-tailed PMO sequence in muscle cells of the mdx mouse model of muscular dystrophy; targeting the polyA-tailed PMO sequence against a splice site of the pre-mRNA encoding mutated dystrophin triggers an alternate splicing event that results in excision of the mutated exon (exon 23) from the pre-mRNA and production of functional dystrophin, as demonstrated by agarose gel electrophoresis.
© 2018 by John Wiley & Sons, Inc. © 2018 John Wiley & Sons, Inc.

Entities:  

Keywords:  cellular PMO uptake; dystrophin pre-mRNA; exon 23 excision; luciferase pre-mRNA; pre-mRNA splicing

Mesh:

Substances:

Year:  2018        PMID: 29927123      PMCID: PMC6020023          DOI: 10.1002/cpnc.51

Source DB:  PubMed          Journal:  Curr Protoc Nucleic Acid Chem        ISSN: 1934-9270


  26 in total

1.  Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.

Authors:  Derek S Youngblood; Susie A Hatlevig; Jed N Hassinger; Patrick L Iversen; Hong M Moulton
Journal:  Bioconjug Chem       Date:  2007 Jan-Feb       Impact factor: 4.774

Review 2.  Pharmacological inhibition of endocytic pathways: is it specific enough to be useful?

Authors:  Andrei I Ivanov
Journal:  Methods Mol Biol       Date:  2008

3.  Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development.

Authors:  S H Kang; M J Cho; R Kole
Journal:  Biochemistry       Date:  1998-05-05       Impact factor: 3.162

Review 4.  Transfection efficiency of cationic lipids with different hydrophobic domains in gene delivery.

Authors:  Defu Zhi; Shubiao Zhang; Bing Wang; Yinan Zhao; Baoling Yang; Shijun Yu
Journal:  Bioconjug Chem       Date:  2010-04-21       Impact factor: 4.774

Review 5.  Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy.

Authors:  Toshifumi Yokota; Emidio Pistilli; William Duddy; Kanneboyina Nagaraju
Journal:  Expert Opin Biol Ther       Date:  2007-06       Impact factor: 4.388

Review 6.  Targeting RNA to treat neuromuscular disease.

Authors:  Francesco Muntoni; Matthew J A Wood
Journal:  Nat Rev Drug Discov       Date:  2011-08-01       Impact factor: 84.694

7.  Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers.

Authors:  Aurélie Goyenvalle; Graziella Griffith; Arran Babbs; Samir El Andaloussi; Kariem Ezzat; Aurélie Avril; Branislav Dugovic; Rémi Chaussenot; Arnaud Ferry; Thomas Voit; Helge Amthor; Claudia Bühr; Stefan Schürch; Matthew J A Wood; Kay E Davies; Cyrille Vaillend; Christian Leumann; Luis Garcia
Journal:  Nat Med       Date:  2015-02-02       Impact factor: 53.440

8.  Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse.

Authors:  C J Mann; K Honeyman; A J Cheng; T Ly; F Lloyd; S Fletcher; J E Morgan; T A Partridge; S D Wilton
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

Review 9.  A chemical view of oligonucleotides for exon skipping and related drug applications.

Authors:  Peter Järver; Liz O'Donovan; Michael J Gait
Journal:  Nucleic Acid Ther       Date:  2013-10-30       Impact factor: 5.486

10.  Elusive sources of variability of dystrophin rescue by exon skipping.

Authors:  Maria Candida Vila; Margaret Benny Klimek; James S Novak; Sree Rayavarapu; Kitipong Uaesoontrachoon; Jessica F Boehler; Alyson A Fiorillo; Marshall W Hogarth; Aiping Zhang; Conner Shaughnessy; Heather Gordish-Dressman; Umar Burki; Volker Straub; Qi Long Lu; Terence A Partridge; Kristy J Brown; Yetrib Hathout; John van den Anker; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  Skelet Muscle       Date:  2015-12-01       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.